Zentalis Pharmaceuticals (NASDAQ:ZNTL) Coverage Initiated by Analysts at Wells Fargo & Company

Equities research analysts at Wells Fargo & Company began coverage on shares of Zentalis Pharmaceuticals (NASDAQ:ZNTL) in a research note issued to investors on Tuesday. The firm set an “equal weight” rating and a $5.00 price target on the stock. Wells Fargo & Company‘s target price would indicate a potential upside of 84.16% from the stock’s previous close.

Zentalis Pharmaceuticals Price Performance

Shares of NASDAQ ZNTL traded up $0.01 during mid-day trading on Tuesday, hitting $2.72. The company had a trading volume of 23,956 shares, compared to its average volume of 1,433,927. Zentalis Pharmaceuticals has a 12 month low of $1.01 and a 12 month high of $3.95. The firm has a market cap of $196.16 million, a P/E ratio of -1.32 and a beta of 1.71. The business’s 50-day simple moving average is $2.66 and its 200-day simple moving average is $1.89.

Insider Buying and Selling

In other news, major shareholder Group Walters acquired 6,459,973 shares of the firm’s stock in a transaction dated Wednesday, December 31st. The shares were bought at an average price of $1.20 per share, with a total value of $7,751,967.60. Following the acquisition, the insider owned 13,509,973 shares of the company’s stock, valued at $16,211,967.60. This trade represents a 91.63% increase in their ownership of the stock. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, insider Vincent Vultaggio sold 29,951 shares of the business’s stock in a transaction that occurred on Friday, February 6th. The shares were sold at an average price of $2.43, for a total value of $72,780.93. Following the sale, the insider owned 156,779 shares in the company, valued at approximately $380,972.97. This represents a 16.04% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders sold a total of 46,617 shares of company stock valued at $113,417 in the last quarter. Corporate insiders own 1.90% of the company’s stock.

Institutional Investors Weigh In On Zentalis Pharmaceuticals

Institutional investors and hedge funds have recently bought and sold shares of the business. SG Americas Securities LLC raised its stake in shares of Zentalis Pharmaceuticals by 35.3% in the 3rd quarter. SG Americas Securities LLC now owns 31,579 shares of the company’s stock valued at $48,000 after buying an additional 8,236 shares in the last quarter. Invesco Ltd. lifted its holdings in shares of Zentalis Pharmaceuticals by 8.6% during the 4th quarter. Invesco Ltd. now owns 188,582 shares of the company’s stock worth $255,000 after acquiring an additional 14,961 shares during the period. Barr E S & Co. boosted its position in shares of Zentalis Pharmaceuticals by 43.8% during the 4th quarter. Barr E S & Co. now owns 57,500 shares of the company’s stock valued at $78,000 after acquiring an additional 17,500 shares in the last quarter. Vanguard Group Inc. boosted its position in shares of Zentalis Pharmaceuticals by 0.7% during the 3rd quarter. Vanguard Group Inc. now owns 2,904,400 shares of the company’s stock valued at $4,386,000 after acquiring an additional 19,768 shares in the last quarter. Finally, Sivia Capital Partners LLC bought a new stake in Zentalis Pharmaceuticals in the fourth quarter valued at about $27,000.

Zentalis Pharmaceuticals Company Profile

Zentalis Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company focused on discovering and developing small molecule therapeutics for oncology. Leveraging a proprietary structure-based drug discovery platform, the company designs selective inhibitors aimed at critical cancer targets. Zentalis’ research and development efforts center on delivering differentiated therapies that address unmet medical needs in solid tumors and hematologic malignancies.

The company’s lead product candidate, ZN-c3, is an orally administered inhibitor of the p53-MDM2 interaction, currently being evaluated in Phase I clinical trials for advanced solid tumors and hematologic cancers.